Tokai Pharmaceuticals Announces Closing of Initial Public Offering

CAMBRIDGE, Mass.--()--Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the closing of its initial public offering of 6,480,000 shares of its common stock at an initial public offering price of $15.00 per share, resulting in gross proceeds of $97.2 million, before underwriting discounts and commissions. All of the shares in the offering were sold by Tokai. The company's common stock is listed on The NASDAQ Global Market under the symbol "TKAI."

BMO Capital Markets, Stifel and William Blair acted as joint book-running managers for the offering. Janney Montgomery Scott acted as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 16, 2014. Copies of the final prospectus relating to this offering may be obtained by contacting: BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 27th Floor, New York, NY 10036, telephone: (800) 414-3627, email: bmoprospectus@bmo.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415) 364-2720, email: SyndicateOps@stifel.com; or from William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, telephone (800) 621-0687, email: prospectus@williamblair.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts

Investor Contact:
Tokai Pharmaceuticals
Lee Kalowski, 617-225-4305
Chief Financial Officer
investors@tokaipharma.com
or
Media Contact:
Pure Communications, Inc.
Sheryl Seapy, 949-903-4750
Sheryl@purecommunicationsinc.com

Release Summary

Tokai Pharmaceuticals Announces Closing of Initial Public Offering

Contacts

Investor Contact:
Tokai Pharmaceuticals
Lee Kalowski, 617-225-4305
Chief Financial Officer
investors@tokaipharma.com
or
Media Contact:
Pure Communications, Inc.
Sheryl Seapy, 949-903-4750
Sheryl@purecommunicationsinc.com